title: Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer.
abstract: Dihydropyrimidine dehydrogenase deficiency is diagnosed more frequently and is now generally accepted as a potentially life-threatening condition. It predisposes patients receiving treatment with fluoropyrimidines such as 5-fluorouracil (5-FU) to severe and, in case of complete dihydropyrimidine dehydrogenase deficiency, often fatal toxicity. A patient who had severe side effects following standard dose adjuvant 5-FU exposure was diagnosed of having hereditary partial dihydropyrimidine dehydrogenase deficiency. When the patient relapsed with liver metastases, we treated him with the non-fluoropyrimidine cytotoxic agents irinotecan, oxaliplatin and raltitrexed in sequential manner, and were able to show that these drugs can be safely applied in patients with this metabolic defect.
authors.affiliation: Abteilung Hämatologie und Onkologie, Medizinische Hochschule Hannover, Germany. Schoeffski.Patrick@MH-Hannover.de
authors.forename: J
authors.initials: J
authors.lastname: Volk
authors.forename: F
authors.initials: F
authors.lastname: Reinke
authors.forename: A B
authors.initials: AB
authors.lastname: van Kuilenburg
authors.forename: A H
authors.initials: AH
authors.lastname: van Gennip
authors.forename: C
authors.initials: C
authors.lastname: Schlichting
authors.forename: A
authors.initials: A
authors.lastname: Ganser
authors.forename: P
authors.initials: P
authors.lastname: Schöffski
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D042943:Dihydrouracil Dehydrogenase (NADP); D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010088:Oxidoreductases / Q000172:deficiency*; D011799:Quinazolines / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage
chemical_list: D009944:Organoplatinum Compounds; D011799:Quinazolines; D013876:Thiophenes; D000077150:Oxaliplatin; D000077146:Irinotecan; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); C068874:raltitrexed; D002166:Camptothecin